SHAREHOLDERS' EQUITY (Details 2) (USD $)	12 Months Ended								12 Months Ended						12 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2009	Jun. 30, 2011 2004 Plan	Oct. 28, 2010 2004 Plan	Jun. 30, 2010 2004 Plan	Jun. 30, 2009 2004 Plan	May 31, 2004 2004 Plan	Jun. 30, 2011 2004 Plan Stock options and SARs	Jun. 30, 2011 2004 Plan RSAs	Jun. 30, 2011 2004 Plan RSUs	Jun. 30, 2011 2000 Plan	Jun. 30, 2010 2000 Plan	Jun. 30, 2009 2000 Plan	Jun. 30, 2011 2000 Plan Incentive stock options, greater than 10 percent voting power	Jun. 30, 2011 2000 Plan Director options	Jun. 30, 2011 RSAs and RSUs	Jun. 30, 2010 RSAs and RSUs	Jun. 30, 2009 RSAs and RSUs	Jun. 30, 2011 RSAs	Jun. 30, 2010 RSAs	Jun. 30, 2009 RSAs	Jun. 30, 2011 RSUs	Jun. 30, 2011 Stock options and SARs	Jun. 30, 2010 Stock options and SARs	Jun. 30, 2009 Stock options and SARs	Jun. 30, 2011 SARs	Jun. 30, 2010 SARs	Jun. 30, 2009 SARs	Jun. 30, 2011 Cash-based performance grants
Stock-based compensation award plans
Common stock authorized for issuance (in shares)					6,750,000			2,500,000
Percentage of stock-based awards vesting annually on each of the first five anniversaries of the date of grant (as a percent)									20.00%	20.00%
Vesting period (in years)									Five years	Five years	Five years									Five years			Five years	Five years						One year
Maximum term of awards (in years)									Ten years			Ten years			Five years	Ten years								Ten years
Shares available for grant (in shares)	4,209,000	16,000	371,000	4,209,000		12,000	103,000						4,000	268,000
Shares previously available for grant (in shares)												3,500,000
Percentage of voting power in excess of which tenure of award would not exceed five years (as a percent)															10.00%
Stock options outstanding
Balance at the beginning of the period (in shares)	980,000	1,385,000	1,713,000
Granted (in shares)		135,000	9,000
Cancelled (in shares)	(96,000)	(337,000)	(102,000)
Exercised (in shares)	(46,000)	(203,000)	(235,000)
Balance at the end of the period (in shares)	838,318	980,000	1,385,000
Exercisable at the end of the period (in shares)	670,198
Stock options, weighted average exercise price
Balance at the beginning of the period (in dollars per share)	$ 29.48	$ 25.55	$ 24.55
Granted (in dollars per share)		$ 18.90	$ 35.15
Cancelled (in dollars per share)	$ 18.89	$ 17.74	$ 30.20
Exercised (in dollars per share)	$ 15.04	$ 15.12	$ 16.60
Balance at the end of the period (in dollars per share)	$ 31.48	$ 29.48	$ 25.55
Exercisable at the end of the period (in dollars per share)	$ 33.22
Outstanding options, maximum intrinsic value (in dollars)	$ 0
Outstanding options, weighted average remaining contractual term (in years)	4.7
Maximum intrinsic value of exercisable options (in dollars)	0
Weighted average remaining contractual term of exercisable options (in years)	3.9
Options expected to vest (in shares)	154,708
Options expected to vest, weighted average exercise price (in dollars per share)	$ 24.81
Options expected to vest, weighted average remaining contractual life (in years)	7.7
Options expected to vest, total intrinsic value (in dollars)	0
Rollforward of RSAs, RSUs and SARs outstanding
Nonvested at the beginning of the period (in shares)																	1,146,000	1,032,000	523,000
Outstanding at the beginning of the period (in shares)																											1,110,000	1,114,000	527,000
Granted (in shares)																	277,000	304,000	618,000								103,000	2,000	632,000
Cancelled (in shares)																	(118,000)	(2,000)	(28,000)								(126,000)	(6,000)	(45,000)
Vested (in shares)																	(228,000)	(188,000)	(81,000)
Nonvested at the end of the period (in shares)																	1,077,000	1,146,000	1,032,000
Outstanding at the end of the period (in shares)																											1,087,460	1,110,000	1,114,000
RSAs, RSUs and SARs outstanding, other relevant terms of the awards
Weighted Average Grant Date Fair Value, nonvested at the beginning of the period (in dollars per share)																	$ 24.70	$ 26.33	$ 36.76
Weighted Average Grant Date Fair Value, Granted (in dollars per share)																	$ 16.60	$ 19.12	$ 19.14	$ 16.60	$ 19.12	$ 19.14					$ 6.26	$ 8.60	$ 7.07
Weighted Average Grant Date Fair Value, Cancelled (in dollars per share)																	$ 20.42	$ 20.02	$ 35.41
Weighted Average Grant Date Fair Value, Vested (in dollars per share)																	$ 22.69	$ 24.74	$ 35.72
Weighted Average Grant Date Fair Value, nonvested at the end of the period (in dollars per share)																	$ 23.48	$ 24.70	$ 26.33
Weighted Average Exercise Price, outstanding at the beginning of the period (in dollars per share)																											$ 26.24	$ 26.30	$ 35.70
Weighted Average Exercise Price, Granted (in dollars per share)																											$ 16.60	$ 28.57	$ 19.14
Weighted Average Exercise Price, Cancelled (in dollars per share)																											$ 24.35	$ 38.63	$ 35.73
Weighted Average Exercise Price, outstanding at the end of the period (in dollars per share)																											$ 25.54	$ 26.24	$ 26.30
Outstanding and unvested awards, intrinsic value																				13,200,000			3,300,000
Outstanding awards, intrinsic value																											0
Outstanding awards, weighted average remaining contractual term (in years)																				2.2			0.7				6.9
Outstanding and unvested awards expected to vest (in shares)																				806,986							459,838
Outstanding and unvested awards expected to vest, total intrinsic value (in dollars)																				12,400,000							0
Exercisable at end of period (in shares)																											604,140
Exercisable at end of period, total intrinsic value (in dollars)																											0
Exercisable at end of period, remaining contractual life (in years)																											6.0
Outstanding and unvested awards expected to vest, weighted average grant price (in dollars per share)																											$ 20.39
Outstanding and unvested awards expected to vest, remaining contractual term (in years)																											8.0
Unvested RSAs with accelerated vesting period held by the company's chief executive officer and the company's executive vice president (in shares)																				68,390
Incremental compensation cost recognized as a result of the modifications																				100,000
Stock-based compensation award plans, additional disclosures
Cash received from exercise of share-based instruments	700,000	3,100,000	3,900,000
Unrecognized compensation cost related to unvested stock-based compensation	20,900,000
Period of recognition of unrecognized compensation cost related to unvested stock-based compensation (in years)	3.1
Intrinsic value of share-based awards exercised	200,000	700,000	1,900,000
Stock options, weighted average grant date fair value (in dollars per share)		$ 7.36	$ 8.60
Compensation expense related to share-based awards	$ 9,600,000	$ 9,300,000	$ 7,500,000
Assumptions used in determining fair value of stock options and SARs
Risk-free interest rate (as a percent)																								2.29%	2.79%
Risk-free interest rate, low end of range (as a percent)																										2.45%
Risk-free interest rate, high end of range (as a percent)																										3.29%
Expected term (in years)																								5.50	5.50	5.50
Expected volatility (as a percent)																								44.00%	42.00%
Expected volatility, low end of range (as a percent)																										28.00%
Expected volatility, high end of range (as a percent)																										40.00%
Expected dividend yield (as a percent)																								1.45%	0.85%
Expected dividend yield, low end of range (as a percent)																										0.56%
Expected dividend yield, high end of range (as a percent)																										0.84%